丰倍生物
(603334)
| 流通市值：10.21亿 | | | 总市值：46.03亿 |
| 流通股本：3181.67万 | | | 总股本：1.44亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 2,346,738,610.6 | 1,108,730,173.16 | 3,170,795,556.18 | 2,251,405,158.14 |
| 营业总成本 | 2,270,316,203.73 | 1,076,029,075.77 | 3,057,754,762.06 | 2,150,718,766.31 |
| 其他经营收益 | | | | |
| 营业利润 | 94,195,730.04 | 46,017,792.1 | 153,953,396.56 | 127,785,313.21 |
| 利润总额 | 92,897,644.47 | 45,841,698.02 | 153,495,480.32 | 127,693,830.05 |
| 净利润 | 81,464,712.83 | 40,911,508.99 | 140,525,241.36 | 117,298,826.48 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 81,464,712.83 | 40,911,508.99 | 140,525,241.36 | 117,298,826.48 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,729,633,822.49 | 1,669,977,396.27 | 1,727,282,875.2 | 937,482,357.13 |
| 非流动资产: | | | | |
| 非流动资产合计 | 520,008,489.52 | 496,473,260.22 | 498,061,456.36 | 498,372,134.24 |
| 资产总计 | 2,249,642,312.01 | 2,166,450,656.49 | 2,225,344,331.56 | 1,435,854,491.37 |
| 流动负债: | | | | |
| 流动负债合计 | 499,445,309.92 | 414,064,060.6 | 491,815,889.42 | 467,338,733.83 |
| 非流动负债: | | | | |
| 非流动负债合计 | 17,354,584.95 | 11,103,089.21 | 33,783,608.64 | 93,543,955.16 |
| 负债合计 | 516,799,894.87 | 425,167,149.81 | 525,599,498.06 | 560,882,688.99 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,729,756,524.84 | 1,739,284,730.78 | 1,697,778,510.26 | 874,971,802.38 |
| 股东权益合计 | 1,732,842,417.14 | 1,741,283,506.68 | 1,699,744,833.5 | 874,971,802.38 |
| 负债和股东权益合计 | 2,249,642,312.01 | 2,166,450,656.49 | 2,225,344,331.56 | 1,435,854,491.37 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,194,141,912.6 | 1,357,863,734.03 | 3,657,137,009.25 | 2,227,148,130.77 |
| 经营活动现金流出小计 | 2,296,857,842.27 | 1,302,513,153.21 | 3,683,575,399.23 | 2,359,900,969.43 |
| 经营活动产生的现金流量净额 | -102,715,929.67 | 55,350,580.82 | -26,438,389.98 | -132,752,838.66 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 401,666,238.97 | 271,026,655.85 | 5,930,528.37 | 2,220,697.27 |
| 投资活动现金流出小计 | 482,024,726.8 | 110,961,785.91 | 329,198,229.98 | 22,322,855.57 |
| 投资活动产生的现金流量净额 | -80,358,487.83 | 160,064,869.94 | -323,267,701.61 | -20,102,158.3 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 185,803,819 | 20,500,000 | 1,195,546,918.6 | 272,483,195.04 |
| 筹资活动现金流出小计 | 225,420,018.43 | 131,840,574.75 | 449,337,428.6 | 191,088,052.1 |
| 筹资活动产生的现金流量净额 | -39,616,199.43 | -111,340,574.75 | 746,209,490 | 81,395,142.94 |
| 汇率变动对现金及现金等价物的影响 | -6,468,927.44 | -2,392,588.47 | -103,225.25 | 2,291,548.32 |
| 现金及现金等价物净增加额 | -229,159,544.37 | 101,682,287.54 | 396,400,173.16 | -69,168,305.7 |
| 期末现金及现金等价物余额 | 318,031,794.88 | 648,873,626.79 | 547,191,339.25 | 81,622,860.39 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -229,159,544.37 | - | 396,400,173.16 | - |